Tivdak

Indicated For

Recurrent or metastatic cervical cancer

About This Medication

# Pfizer Oncology Together Patient Guide: How to Get Tivdak (tisotumab vedotin-tftv) at Low or No Cost Tivdak (tisotumab vedotin-tftv) is a prescription medication used to treat adults with **recurrent or metastatic cervical cancer** after their disease has progressed on or after chemotherapy. The **Pfizer Oncology Together** program, offered by Seagen, Inc. (a Pfizer company), provides financial assistance to help eligible patients access Tivdak at low or no cost, including co-pay support and options for those with Medicare Part D.[1][2][3] ## About Tivdak Tivdak is an **antibody-drug conjugate (ADC)** that targets tissue factor (TF) on cancer cells. It binds to TF-expressing cells, gets internalized, and releases monomethyl auristatin E (MMAE), which disrupts microtubules, leading to cell cycle arrest and cancer cell death. It was granted accelerated FDA approval in September 2021 based on tumor response and durability from the innovaTV 204 trial, with ongoing confirmatory data from the Phase 3 innovaTV 301 trial showing benefits in overall survival, progression-free survival, and response rates compared to chemotherapy.[1] **Important warnings**: Tivdak has a boxed warning for **ocular adverse reactions** (e.g., blurred vision, dry eyes—requires eye exams before and during treatment), **fatal hemorrhage** (monitor for bleeding like epistaxis or vaginal hemorrhage), **severe peripheral neuropathy**, and **pneumonitis**. Common side effects include fatigue, nausea, anemia, and diarrhea. Always follow your doctor's guidance, premedication, and eye care instructions.[1][2] Tivdak is infused every 3 weeks by a healthcare provider. It's for patients with squamous cell, adenocarcinoma, or adenosquamous cervical cancer histology.[1] ## Who Qualifies for Pfizer Oncology Together? This program helps patients afford Tivdak through co-pay assistance, free medicine for uninsured/underinsured, and reimbursement support. Eligibility focuses on financial need and insurance status, but **specific income thresholds are not publicly published**—you must call the program for personalized details.[10] General eligibility includes: - U.S. residents prescribed Tivdak. - Financial hardship (income-based, details via phone). - Commercial insurance, Medicare Part D, or uninsured. | Household Size | Income Threshold (Federal Poverty Level) | Notes | |---------------|-----------------------------------------|-------| | Individual | Not published; call (877) 744-5675 | Program assesses case-by-case. | | Couple | Not published; call (877) 744-5675 | May cover up to certain FPL %; confirm eligibility. | | Family of 3 | Not published; call (877) 744-5675 | Varies by state and situation. | | Family of 4 | Not published; call (877) 744-5675 | Contact for exact guidelines. | **Key note**: Even if income details aren't listed online, many patients qualify regardless of income for co-pay help (e.g., commercially insured pay as little as $0/month, limits apply).[4][7] Uninsured patients may get free medicine.[2][9] ## Insurance Requirements - **Commercial insurance**: Eligible for co-pay savings via Pfizer Oncology Together Co-Pay Portal—pay $0 per treatment for eligible patients.[5][7] - **Medicare Part D**: Patients **may be eligible**; co-payment assistance and reimbursement support available. A Field Reimbursement Director (FRD) can help navigate coverage.[3][4][10] - **Uninsured/underinsured**: Free or low-cost medicine options. Your doctor or FRD will verify if Tivdak is a medical or pharmacy benefit and handle prior authorizations.[2] ## Step-by-Step Application Process The program uses **multiple application methods** (phone, online, fax forms).[9][10] 1. **Discuss with your doctor**: Confirm Tivdak prescription. Provide physician's DEA, State NPI license numbers, and signature.[10] 2. **Contact the program**: Call **(877) 744-5675** (Mon-Fri, hours vary) or visit Pfizer Oncology Together site to start. Request HCP Request Form and Patient Enrollment Form.[2][9] 3. **Gather documents**: - Front and back of insurance cards (if applicable). - Physician DEA and State NPI numbers. - Physician signature. - Proof of income/residency if requested (call for details).[10] 4. **Submit application**: Fax, mail, or online via Seagen Secure (for Tivdak) or Pfizer Copay Portal. Submit forms together for faster processing.[2][5] 5. **Get assigned support**: An FRD contacts you for personalized help, coverage appeals, and resources.[4] 6. **Approval and start**: Once approved, medicine ships or co-pay card activates. ## Timeline and Delivery **Processing time**: Not specified—call for estimate, but aim to submit complete forms together.[2] Claims and payments follow enrollment.[5] **Delivery method**: **Varies** (direct to provider, pharmacy, or patient home). Co-pay savings at infusion site.[2][5] ## Refills and Reauthorization **Reauthorization**: Not specified—likely required periodically; your doctor resubmits. Monitor treatment cycle (every 3 weeks).[2] Refills via ongoing enrollment; contact program for renewals. ## Alternatives if Denied - **Appeal**: Work with FRD for prior authorization or coverage appeals.[2][4] - **Other assistance**: Patient Access Network (PAN) Foundation, HealthWell Foundation, or CancerCare for cervical cancer support. - **Free trial/sample**: Ask doctor about manufacturer samples. - **Biosimilars**: None available.[10] - **State programs**: Check NeedyMeds or RxAssist for local options. If denied, call (877) 744-5675 immediately—many denials are reversible with more info. ## Disclaimer This guide is for informational purposes only and based on publicly available data as of 2026. Eligibility, terms, and availability can change—**always verify directly with Pfizer Oncology Together at (877) 744-5675**. Not medical advice; consult your healthcare provider. Program not for government-insured except as noted. Limits/terms apply (e.g., co-pay caps).[4][7][10] Seagen/Pfizer reserves rights to modify/amend anytime.

Program information last verified: March 25, 2026